Laboratory Corporation of America Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Laboratory of America Holdings' es Adam Schechter , nombrado en Nov 2019, tiene una permanencia de 4.42 años. compensación anual total es $15.98M, compuesta por 8.6% salario y 91.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de MX$320.30M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 10.2 años, respectivamente.

Información clave

Adam Schechter

Chief Executive Officer (CEO)

US$16.0m

Compensación total

Porcentaje del salario del CEO	8.6%
Permanencia del CEO	4.5yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	10.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adam Schechter en comparación con los beneficios de Laboratory Corporation of America Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$399m
Dec 31 2023	US$16m	US$1m	US$379m
Sep 30 2023	n/a	n/a	US$583m
Jun 30 2023	n/a	n/a	US$677m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$15m	US$1m	US$1b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$21m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$3b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$15m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$845m
Jun 30 2020	n/a	n/a	US$362m
Mar 31 2020	n/a	n/a	US$321m
Dec 31 2019	US$6m	US$208k	US$824m
Sep 30 2019	n/a	n/a	US$755m
Jun 30 2019	n/a	n/a	US$853m
Mar 31 2019	n/a	n/a	US$896m
Dec 31 2018	US$301k	n/a	US$884m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$290k	n/a	US$1b

Compensación vs. Mercado: La compensación total de Adam($USD15.98M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD6.04M).

Compensación vs. Ingresos: La compensación de Adam ha sido consistente con los resultados de la empresa en el último año.

CEO

Adam Schechter (58 yo)

4.5yrs

Permanencia

US$15,979,355

Compensación

Mr. Adam H. Schechter serves as President & Chief Executive Officer at Laboratory Corporation of America Holdings since November 01, 2019 and serves as its Chairman since May 13, 2020. He serves as Indepen...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Adam Schechter	President	4.5yrs	US$15.98m	0.11% $ 318.9m
Glenn Eisenberg	CFO & Executive VP	9.9yrs	US$4.96m	0.055% $ 157.6m
Mark Schroeder	Executive VP	less than a year	US$3.80m	0.0060% $ 17.1m
Brian Caveney	EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	less than a year	US$3.48m	0.033% $ 95.0m
Anita Graham	Executive VP & Chief Human Resources Officer	1.3yrs	US$2.56m	0.00035% $ 1.0m
Peter Wilkinson	Senior VP & Chief Accounting Officer	5.1yrs	sin datos	0.0025% $ 7.1m
Lance Berberian	Executive VP and Chief Information & Technology Officer	10.3yrs	US$2.70m	0.033% $ 95.4m
Christin O'Donnell	Vice President of Investor Relations	no data	sin datos	sin datos
Sandra van der Vaart	Executive VP	5.3yrs	sin datos	0.0091% $ 26.0m
Amy Summy	Executive VP & Chief Marketing Officer	4.2yrs	sin datos	0.0047% $ 13.6m
Marcia Eisenberg	Enterprise Chief Scientific Officer & Senior VP	no data	sin datos	sin datos
Deborah Sesok-Pizzini	Chief Medical Officer	3.3yrs	sin datos	sin datos

4.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LH * se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Adam Schechter	President	11.1yrs	US$15.98m	0.11% $ 318.9m
Peter Neupert	Independent Director	11.3yrs	US$357.87k	0.014% $ 40.7m
Kerrii Anderson	Independent Director	18yrs	US$340.73k	0.019% $ 54.5m
Jean-Luc Belingard	Independent Director	29.1yrs	US$330.31k	0.021% $ 60.5m
Garheng Kong	Lead Independent Director	10.4yrs	US$375.73k	0.014% $ 40.5m
Richelle Parham	Independent Director	8.3yrs	US$341.44k	0.010% $ 29.1m
R. Williams	Independent Director	17yrs	US$350.01k	0.0096% $ 27.6m
D. Gilliland	Independent Director	10.1yrs	US$330.01k	0.010% $ 29.7m
Jeffrey Davis	Independent Director	4.4yrs	US$344.30k	0.0043% $ 12.3m
Paul Rothman	Director	less than a year	US$208.42k	0.000020% $ 57.4k
Kathryn Wengel	Independent Director	3.2yrs	US$330.01k	0.0027% $ 7.8m
Kirsten Kliphouse	Independent Director	1.6yrs	US$330.01k	0.0016% $ 4.5m

10.3yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de LH * son experimentados ( 10.2 años antigüedad media).

Laboratory Corporation of America Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Independent Director recently sold Mex$18m worth of stock

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

Labcorp Announces Executive Changes

Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors

Recent updates

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold Mex$18m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022)

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023

Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023

Labcorp Announces Executive Changes

Upcoming dividend of US$0.72 per share

Now 21% undervalued

Third quarter 2022 earnings released: EPS: US$3.91 (vs US$6.10 in 3Q 2021)

Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors

Labcorp Declares Quarterly Dividend, Payable on December 9, 2022

Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets.

Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022

Executive VP recently bought Mex$205k worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health.

Upcoming dividend of US$0.72 per share

Senior VP & Chief Accounting Officer recently sold Mex$9.5m worth of stock

Laboratory Corporation of America Holdings Launches Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test

Laboratory Corporation of America Holdings to Report Q2, 2022 Results on Jul 28, 2022

Labcorp to Begin Testing for Monkeypox Using the U.S. Centers for Disease Control and Prevention’s Othopoxvirus Test

Executive VP recently bought Mex$199k worth of stock

Labcorp Launches New Test for People with Skin Cancer

Laboratory Corporation of America Holdings (NYSE:LH) acquired Select Assets from the Clinical Outreach Business of AtlantiCare.

Labcorp Launches Convenient Home Diagnostic Test Collection Service in Collaboration With Getlabs

Labcorp Initiates Quarterly Dividend, Payable on June 9, 2022

Laboratory Corporation of America Holdings, Annual General Meeting, May 11, 2022

Laboratory Corporation of America Holdings to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Personal Genome Diagnostics Inc.

Laboratory Corporation of America Holdings Provides Earning Guidance of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Labcorp Launches Labcorp OnDemand Digital Health Platform

Laboratory Corporation of America Holdings (NYSE:LH) entered into a definitive agreement to acquire Personal Genome Diagnostics Inc for $580 million.

Independent Director recently sold Mex$3.2m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) announces an Equity Buyback for $2,500 million worth of its shares.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Toxikon Corp.

Third quarter 2021 earnings released: EPS US$6.10 (vs US$7.22 in 3Q 2020)